SCHEMBL266520

SCHEMBL266520

Cc1ccc(/C=N/NC(=O)c2cc(Cl)ccc2NC(=O)c2ccncc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.65
KMT2A Q03164 7/20 0.58
MEN1 O00255 4/20 0.58
POLB P06746 3/20 0.58
ALDH1A1 P00352 3/20 0.58
TDP1 Q9NUW8 2/20 0.58
KDM4E B2RXH2 2/20 0.58
NPC1 O15118 5/20 0.57
RAB9A P51151 5/20 0.57
PKM P14618 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.56
MAPT P10636 3/20 0.55
RECQL P46063 1/20 0.55
CTDSP1 Q9GZU7 1/20 0.53
PSMD14 O00487 1/20 0.53
THRB P10828 1/20 0.53
HPGD P15428 1/20 0.53
MITF O75030 1/20 0.51
GPR174 Q9BXC1 1/20 0.51
MPO P05164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266521 1.00 L3MBTL1 (0.65) L3MBTL1KMT2AMEN1POLBALDH1A1
SCHEMBL269060 0.90 NPC1 (0.53) L3MBTL1KMT2AMEN1POLBALDH1A1
SCHEMBL269059 0.90 NPC1 (0.53) L3MBTL1KMT2AMEN1POLBALDH1A1
SCHEMBL266740 0.90 SMN1; SMN2 (0.59) L3MBTL1KMT2AMEN1POLBALDH1A1
SCHEMBL266741 0.90 SMN1; SMN2 (0.59) L3MBTL1KMT2AMEN1POLBALDH1A1
SCHEMBL265302 0.89 CYP2D6 (0.55) L3MBTL1KMT2AMEN1POLBALDH1A1
SCHEMBL265301 0.89 CYP2D6 (0.55) L3MBTL1KMT2AMEN1POLBALDH1A1
SCHEMBL268847 0.88 KMT2A (0.55) KMT2AMEN1POLBALDH1A1TDP1
SCHEMBL268846 0.88 KMT2A (0.55) KMT2AMEN1POLBALDH1A1TDP1
SCHEMBL266537 0.88 L3MBTL1 (0.65) L3MBTL1KMT2AMEN1POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 L3MBTL1 934/4885KMT2A 4564/4885MEN1 1194/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 L3MBTL1 1096/4885KMT2A 4603/4885MEN1 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.